| PE25.03 | Patterns of adherence among South African women in a phase III randomized controlled trial of a dapivirine vaginal ring for HIV-1 prevention | E-poster | Product acceptability and adherence |
| PE25.02 | Impact of women's home environment on use of the dapivirine ring for HIV prevention in MTN-025/HOPE | E-poster | Product acceptability and adherence |
| PE25.01 | What women want in a multipurpose vaginal ring: findings from a phase 1 trial in the U.S. and the Dominican Republic | E-poster | Product acceptability and adherence |
| PE24.05LB | Induction of neutralization breadth and broadly neutralizing antibody lineage responses in HIV envelope BG505 SOSIP immunized infant macaques | E-poster | Preclinical studies for HIV prevention |
| PE24.04LB | Dose response to tenofovir disoproxil fumarate and tenofovir released via intravaginal ring in the sheep vaginal safety and pharmacokinetics model | E-poster | Preclinical studies for HIV prevention |
| PE24.02 | Transport and permeability properties of dapivirine: understanding potential drug-drug interactions | E-poster | Preclinical studies for HIV prevention |
| PE24.01 | Efficacy of a vaginal ring containing the gp120 blocker DS003 in pigtailed macaques | E-poster | Preclinical studies for HIV prevention |
| PE23.07LB | Planning for voluntary medical male circumcision (VMMC) program sustainability: generating evidence to support targeted transition planning in Zambia and Zimbabwe using the VMMC Transition Assessment Dashboard-VTAD | E-poster | Policy and advocacy |
| PE23.06LB | HIV prevention research and development funding trends 2000'2019: investment priorities to fund innovation in a challenging global health landscape | E-poster | Policy and advocacy |
| PE23.04 | Pathogen reduction (PR) as an alternative to donor deferral to mitigate the risk of transfusion-transmitted HIV | E-poster | Policy and advocacy |